Femoro-popliteal Arterlerdeki Kronik Total Oklüzyon Tedavisinde İopromid Bazlı Paklitaksel Kaplı Balonun On İki Aylık Sonuçları

dc.authorscopusid58146121500
dc.authorscopusid55754659100
dc.authorscopusid35195470300
dc.contributor.authorÖzpak, H.B.
dc.contributor.authorAydın, Cihan
dc.contributor.authorDemırkıran, Aykut
dc.date.accessioned2023-05-06T17:23:33Z
dc.date.available2023-05-06T17:23:33Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractOBJECTIVE: We designed a retrospective study to evaluate the performance and outcomes of a novel iopromide-based paclitaxel-coated balloon for the treatment of chronic total occlusion of femoropopliteal arteries. METHODS: Patients with femoropopliteal chronic total occlusion (<100 mm) on angiogram were screened from hospital management system and were included in the study. The width and length of the drug-eluting peripheral balloon was chosen to ensure a vessel/balloon ratio of 1: 1 and exceed the lesion by 10 mm on both ends (based on visual estimation). RESULTS: The proportion of patients with ankle-brachial index improvement was 89.8% (106 of 118). The mean ankle-brachial index was 0.5 (0.4-0.7) at baseline and 0.8 (0.7-0.9) at 12 months (P < 0.001). Changes in the Rutherford category between baseline and 12 months were statistically signi?cant (P < 0.001), with the majority of patients (77.9%, 92/118) having ?1 level improvement. The rate of clinically driven target lesion revasculariza-tion at 12 months was 13.5%(16/118). Overall, the 1-year primary patency rate was 86.4% (102 of 118). The major adverse limb event rate was 9.8% (16/162). Acute limb ischemia was detected in 14 patients, and amputation was performed in 2 patients. CONCLUSION: Our study is a non-randomized clinical study focusing on the use of drug-eluting balloon as a single treatment strategy. There was signi?cant clinical bene?t to patients, as clearly demonstrated by the improvement in ankle-brachial index and the reduction in Rutherford class in the short term, and these results may o?er clear insights on the revascularization strategy outlook of interventionalists.
dc.identifier.doi10.5543/tkda.2022.25324
dc.identifier.endpage118
dc.identifier.issn1308-4488
dc.identifier.issue2en_US
dc.identifier.pmid36916806
dc.identifier.scopus2-s2.0-85150311158
dc.identifier.scopusqualityQ4
dc.identifier.startpage112
dc.identifier.trdizinid1169242
dc.identifier.urihttps://doi.org/10.5543/tkda.2022.25324
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12150
dc.identifier.volume51
dc.identifier.wosWOS:000999031100006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorAydın, Cihan
dc.institutionauthorDemırkıran, Aykut
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofTurk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectcardiovascular agent
dc.subjectiopromide
dc.subjectpaclitaxel
dc.subjectclinical trial
dc.subjectfemoral artery
dc.subjecthuman
dc.subjectpercutaneous transluminal angioplasty
dc.subjectperipheral arterial disease
dc.subjectpopliteal artery
dc.subjectprocedures
dc.subjectretrospective study
dc.subjecttreatment outcome
dc.subjectAngioplasty, Balloon
dc.subjectCardiovascular Agents
dc.subjectFemoral Artery
dc.subjectHumans
dc.subjectPaclitaxel
dc.subjectPeripheral Arterial Disease
dc.subjectPopliteal Artery
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.titleFemoro-popliteal Arterlerdeki Kronik Total Oklüzyon Tedavisinde İopromid Bazlı Paklitaksel Kaplı Balonun On İki Aylık Sonuçları
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12150.pdf
Boyut:
1.71 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text